Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof

An antibody construct comprising

• a) a first 4-1BB antigen-binding domain derived from an agonistic anti-4-1BB antibody, and
• b) a first folate receptor-α (FRα) antigen-binding domain in a Fab format comprising a heavy chain variable domain (VH) comprising the three heavy chain CDR sequences of antibody 8K22 and a light chain variable domain (VL) comprising the three light chain CDR sequences of antibody 8K22,
• wherein the first 4-1BB antigen-binding domain and the first FRα antigen-binding domain are linked directly or indirectly to a scaffold.

An antibody construct comprising:

• a) a first 4-1BB antigen-binding domain derived from an agonistic anti-4-1BB antibody, and
• b) a first folate receptor-α (FRα) antigen-binding domain comprising a heavy chain variable domain (VH) comprising the three heavy chain CDR sequences of antibody 2L16 and a light chain variable domain (VL) comprising the three light chain CDR sequences of antibody 2L16,
• wherein the first 4-1BB antigen-binding domain and the first FRα antigen-binding domain are linked directly or indirectly to a scaffold.

An antibody construct or antigen-binding fragment thereof, that specifically binds to folate receptor-α (FRα), comprising:

• a heavy chain variable domain (VH) sequence comprising three heavy chain complementarity-determining regions (CDRs) and a light chain variable domain (VL) sequence comprising three light chain CDRs, wherein the heavy chain CDRs and the light chain CDRs are from antibody 2L16.

Use of an effective amount of the antibody construct according to any one of 83 to 90, for the treatment of cancer in a subject in need thereof.